Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).

Our multi-modal investigational drug, efruxifermin (EFX), is designed to treat MASH holistically. EFX has been engineered to mimic the biological activity of fibroblast growth factor 21 …

Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).

Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on …

Feb 28, 2025 · Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, …

Jan 27, 2025 · Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send …

3 days ago · Akero's SYMMETRY is the only study to show histologic reversal of cirrhosis (F4) in a meaningful proportion of patients (39%) with placebo control — making it a standout result in …

Student media plans with precise targeting and customized recommendations, powered by billions of data points, with live reporting on every metric that matters. Create next gen forms instantly, …

Akero is a clinical-stage company developing transformational medicines for people with serious metablic diseases such as MASH.